secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenetic Biosciences, Inc. (XBIO)
CIK:        0001534525
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001683168-25-006001
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenetic Biosciences Q2 2025 net loss $0.7M; cash $4.8M; expands Scripps partnership
--------------------------------------------------------------------------------

- Net loss ~$0.7M for Q2 2025; no revenue reported.
- R&D expenses fell 29.7% to ~$0.7M; G&A down 41.8% to ~$0.7M vs Q2 2024.
- Cash at quarter-end ~$4.8M to fund operations.
- Expanded collaboration with Scripps Research Institute for DNase I plus CAR T-cell studies.
- Partner PeriNess commenced patient dosing in pancreatic cancer study; exploratory CAR T study in large B cell lymphoma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534525/000168316825006001/0001683168-25-006001-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534525/000168316825006001/xenetic_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-25-006001

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer